These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38376912)

  • 1. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
    Mamounas EP; Bandos H; Rastogi P; Zhang Y; Treuner K; Lucas PC; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil S; Paik S; Swain SM; Sgroi DC; Schnabel CA; Wolmark N
    Clin Cancer Res; 2024 May; 30(9):1984-1991. PubMed ID: 38376912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
    Rastogi P; Bandos H; Lucas PC; van 't Veer LJ; Wei JJ; Geyer CE; Fehrenbacher L; Chia SKL; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Paik S; Swain SM; Menicucci AR; Audeh MW; Wolmark N; Mamounas EP
    J Clin Oncol; 2024 Oct; 42(30):3561-3569. PubMed ID: 39047219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
    Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
    Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
    Mamounas EP; Bandos H; Rastogi P; Lembersky BC; Jeong JH; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Wade JL; McCarron EC; Swain SM; Wolmark N
    J Natl Cancer Inst; 2023 Nov; 115(11):1302-1309. PubMed ID: 37184928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
    Sgroi DC; Carney E; Zarrella E; Steffel L; Binns SN; Finkelstein DM; Szymonifka J; Bhan AK; Shepherd LE; Zhang Y; Schnabel CA; Erlander MG; Ingle JN; Porter P; Muss HB; Pritchard KI; Tu D; Rimm DL; Goss PE
    J Natl Cancer Inst; 2013 Jul; 105(14):1036-42. PubMed ID: 23812955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Mamounas EP; Bandos H; Lembersky BC; Jeong JH; Geyer CE; Rastogi P; Fehrenbacher L; Graham ML; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Seay TE; Wade JL; McCarron EC; Paik S; Swain SM; Wickerham DL; Wolmark N
    Lancet Oncol; 2019 Jan; 20(1):88-99. PubMed ID: 30509771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga RC; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Clin Cancer Res; 2022 May; 28(9):1871-1880. PubMed ID: 35144966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
    Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
    Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
    Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
    Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
    Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
    J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
    Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
    Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
    Colleoni M; Giobbie-Hurder A; Regan MM; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Láng I; Smith I; Chirgwin J; Pienkowski T; Wardley A; Price KN; Gelber RD; Coates AS; Goldhirsch A
    J Clin Oncol; 2011 Mar; 29(9):1117-24. PubMed ID: 21321298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X; Li Z; Ruan G; Tu C; Ding W
    Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.